Glenmark Pharmaceuticals informs about media release
Glenmark Pharmaceuticals has informed that the company research-led, global pharmaceutical company, today announced the launch of GLIPIQ® (semaglutide) in India for the management of Type 2 Diabetes Mellitus (T2DM), setting a new benchmark in affordability for GLP-1 therapy and expanding access to advanced diabetes treatment for patients. The company has attached media release.
The above information is a part of company’s filings submitted to BSE.
